620 results on '"Lussier, Firoza"'
Search Results
102. Late‐life hypertension acts together with amyloid‐β pathology to promote early cognitive decline.
103. Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials.
104. Association between Anxiety and Disease Pathophysiology in Participants of Longitudinal Observational Studies in Aging during the COVID-19 Lockdown
105. Intrinsic connectivity of the human brain provides scaffold for tau aggregation in clinical variants of Alzheimer’s disease
106. APOEε4 carriership associates with microglial activation independently of Aβ plaques and tau tangles
107. The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [18F]MK6240 Tau PET in Target Regions.
108. Performance of plasma amyloid, tau, and astrocyte biomarkers to identify cerebral AD pathophysiology
109. Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET
110. Mitochondrial complex I abnormalities underlie neurodegeneration and cognitive decline in Alzheimer’s disease
111. Associations between neutrophils and amyloid deposition in the Alzheimer’s disease spectrum
112. Visual memory test equal to commonly used verbal memory test in predicting tau in the medial temporal lobe
113. Discrepancy between plasma pTau181 and tau‐PET statuses
114. Plasma p‐Tau181 and p‐Tau231 offer complementary information to identify Alzheimer's disease pathophysiology
115. Adapting to the COVID‐19 pandemic in cohort studies: Validation of online assessments of cognition and neuropsychiatric symptoms in an aging population
116. Tau accumulation using [18F]MK6240 PET is associated with increase in executive dysfunction in prodromal AD
117. Effect of temporal meta‐ROI and Braak1&2 ROI on the dissociation between plasma pTau181 and PET statuses
118. Verbal fluency associated with tau accumulation and not amyloid deposition in the Alzheimer’s disease spectrum
119. Cognitive health mediates the effect of hippocampal volume on COVID‐19‒related knowledge or anxiety change during the COVID‐19 pandemic
120. Microglial activation and tau propagate jointly across Braak stages
121. COVID‐19 pandemic: Quantifying the effects of the first lockdown on behavioral and cognitive measures using TASIC
122. Tau‐load in the lingual gyrus impacts anxiety levels during the COVID‐19 pandemic in participants of longitudinal observational studies in aging
123. Visual memory scores are associated with lateralization of tau in the medial temporal lobe
124. Cognitive reserve: Evaluating the relationship between WASI‐II Matrix Reasoning and tau accumulation using [18F]MK6240 in monolingual and bilingual individuals
125. The neuroinflammation signatures in different stages of the Alzheimer’s disease continuum
126. Tau‐PET is associated with knowledge of COVID‐19, COVID‐19‐related distress, and change in sleep quality during the pandemic
127. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
128. Medial temporal tau predicts memory decline in cognitively unimpaired elderly.
129. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages
130. Discordance and Concordance Between Cerebrospinal and [18F]FDG-PET Biomarkers in Assessing Atypical and Early-Onset AD Dementia Cases.
131. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the alzheimer's disease neuroimaging initiative
132. [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer's disease.
133. Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex
134. Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease
135. Frequency of biologically-defined AD in relation to age, sex, APOEε4 and cognitive impairment
136. Intrinsic connectivity of the human brain provides scaffold for tau aggregation in clinical variants of Alzheimer's disease
137. Tau deposition assessed by [ 18 F]MK6240 PET is associated with longitudinal decrease in grey matter density across the spectrum of Alzheimer’s disease
138. Interaction between amyloid and neuroinflammation on apathy along the Alzheimer’s disease spectrum
139. [ 18 F]MK‐6240 depicts early and late Braak stages of neurofibrillary tangles in preclinical and symptomatic subjects
140. Association between left hemisphere MK6240 uptake and language dysfunction in aging and Alzheimer’s disease
141. APOE4 packs a punch in women: Sex‐specific vulnerability for tau and neuroinflammation
142. Neuroinflammation is associated with non‐REM sleep reduction in individuals without dementia
143. Amyloid (a), tau (t) and voxel‐based morphometry (n) correlates of visual memory performance
144. Microglial sex dimorphism poses greater vulnerability to Alzheimer’s disease in females: A cross‐species study
145. Monitoring disease pathophysiology longitudinally using multiparametric PET acquisitions: The McGill TRIAD cohort
146. Modeling the trajectory of tau deposition in autosomal‐dominant Alzheimer’s disease using the high‐affinity tau tracer [ 18 F]MK6240
147. Frontal tau pathology underlies behavioural / dysexecutive clinical presentations of Alzheimer’s disease
148. Cerebral amyloid deposition correlates with objectively measured sleep dysfunction
149. Medial temporal neuroinflammation unleashes tau spreading over the neocortex
150. Discordance and Concordance Between Cerebrospinal and [18F]FDG-PET Biomarkers in Assessing Atypical and Early-Onset AD Dementia Cases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.